Trade MGNX anytime, even after market hours
Regulated by
MAS
Trusted by
400,000+ users
MacroGenics, Inc. (MGNX) is trading at US$4.01, down 1.84% today as of Aug 28, 12:58 EDT. The company has a market capitalisation of US$261.17M. Over the past 52 weeks, MGNX has traded between US$1.29 and US$5.08. On Syfe you can trade MGNX with $0 commission and add it to your watchlist.
| Previous close | US$4.08 |
|---|---|
| Market cap | US$261.17M |
| 52-week range | US$1.29 – US$5.08 |
| Volume | 319.94K |
| Exchange | US |
Add to Watchlist
Set Price Alert
MacroGenics, Inc.
MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.
Year: 2013
MacroGenics Closes Sale of Manufacturing Operations to Bora Pharmaceuticals
Jul 2, 4:06 PM · MT Newswires
MacroGenics to Receive $24.5 Million in Regulatory Milestone Payment
Jun 22, 8:55 PM · MT Newswires
MacroGenics to Sell GMP Manufacturing Operations to Bora Pharmaceuticals for $122.5 Million
May 11, 9:57 PM · MT Newswires
MacroGenics Expands ZYNYZ Royalty Deal With Sagard Healthcare Partners
May 4, 12:50 PM · MT Newswires
MacroGenics, Inc. (MGNX) stock is trading at US$4.01, -1.84% from the previous close of US$4.08.
The market cap for MacroGenics, Inc. (MGNX) stock is approximately US$261.17M.
The 52-week high for MacroGenics, Inc. (MGNX) stock is US$5.08.
The 52-week low for MacroGenics, Inc. (MGNX) stock is US$1.29.
MacroGenics, Inc. (MGNX) does not currently pay a dividend.
Stay on top of MGNX
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
